CRDF Q2 2017 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$137M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$102,011-1.3% YoY

Gross Profit

-$236,192-231.5% margin

Operating Income

-$6M-5772.2% margin

Net Income

-$8M-7887.2% margin

EPS (Diluted)

$-18.69

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$775,385

Balance Sheet

Total Assets

$13M

Total Liabilities

$9M

Stockholders' Equity

$4M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102,011	$103,400	-1.3%
Gross Profit	-$236,192	-$306,063	+22.8%
Operating Income	-$6M	-$10M	+41.0%
Net Income	-$8M	-$10M	+21.1%